Vanqua Bio

We were pleased to join the academia and industry professionals at the 16th annual Parkinson’s Disease Therapeutics Conference hosted by The Michael J. Fox Foundation for Parkinson's Research. It was a wonderful opportunity to connect with fellow leaders committed to developing innovative and critically needed therapies for #ParkinsonsDisease. Jack Beyer, Kevin Hunt, Omer Siddiqui, Jonathan Silverstein, Daniel Ysselstein, Adam Knight, PhD

A warm welcome to Maurizio Facheris, M.D. who joined Vanqua Bio as Chief Medical Officer. Dr. Facheris’ first-hand experience of taking #ParkinsonsDisease therapies from early phase development to approval will be instrumental as the company advances VQ-101 into late-stage development.    Dr. Facheris’ previous experience includes the roles of Senior Medical Director in Neuroscience Development at AbbVie and Senior Associate Director of Research Programs at the Michael J. Fox Foundation for Parkinson’s Research. https://lnkd.in/eqRzbQct

We are pleased to share positive interim results from our Phase 1 clinical study of VQ-101, a small molecule allosteric activator of GCase. In healthy volunteers in Phase 1a, VQ-101 demonstrated good tolerability, robust lysosomal GCase activation, and pharmacokinetics consistent with once daily dosing. The study, conducted at Centre for Human Drug Research, has advanced to the Phase 1b portion in patients with Parkinson’s disease. https://lnkd.in/eqRzbQct

Vanqua Bio will participate in two upcoming scientific conferences: Grand Challenges in Parkinson’s Disease Symposium and International Parkinson and Movement Disorder Society's #MDSCongress. For details, read the full press release: https://lnkd.in/eSQp-FQR   #ParkinsonsDisease

Please join us in welcoming Tim Daly to the Finance team at Vanqua Bio. Tim is joining us as Vice President of Finance and Corporate Controller and will play a key role in managing our operational and finance infrastructure. We are excited to have Tim on the team and we can’t wait to see what he accomplishes in his career at Vanqua Bio. #Welcometotheteam #VanquaBio

Today, on #WorldBrainDay, Vanqua Bio joins the neurological community to raise critical awareness of brain health. Neurological disorders can affect anyone, regardless of age, ethnicity, gender or socioeconomic status. Everyone has a human right to brain health. Our team remains committed to discovering and developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including #ParkinsonsDisease. To learn more about #WBD2024, go to https://lnkd.in/dQiTq4FU

We look forward to the inaugural GBA1 meeting hosted by The Neuro (Montreal Neurological Institute-Hospital) exclusively tailored for health professionals and stakeholders specializing in GBA1 research. As both a presenter and a sponsor, we are eager to connect with fellow experts to advance our collective understanding of and treatment of GBA1-associated neurodegenerative diseases. For more details on our presentation, visit: https://bit.ly/4c6csY3

We welcome Hunter Smith to Vanqua Bio’s Board of Directors. With over 30 years of leadership experience in global finance and management roles across multiple industries, Hunter brings a wealth of expertise and strategic vision to our team. As CFO of Rhythm Pharmaceuticals since 2017, Hunter led the company's IPO and subsequently raised additional capital totaling over $1 billion. Previously, Hunter made significant contributions at Celgene and Bunge Limited, and served on the boards of Aeglea BioTherapeutics and Genessee & Wyoming Inc. Hunter will work with the Board of Directors and the executive team to help strengthen our organization as we progress our evolution as a clinical-stage company. #NewBoardMember #Leadership

Our team took part at The Michael J. Fox Foundation for Parkinson's Research, Chicago Run/Walk this past Sunday. It was inspiring to see so many come together in support of a future without #Parkinsons.